Published online Aug 14, 2018. doi: 10.3748/wjg.v24.i30.3426
Peer-review started: March 28, 2018
First decision: May 9, 2018
Revised: May 24, 2018
Accepted: June 22, 2018
Article in press: June 22, 2018
Published online: August 14, 2018
Processing time: 139 Days and 16 Hours
Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer in the world. Although treatment for HCC, including surgical resection, has improved over the past decades, its overall survival rate remains devastatingly high due to its high rate of recurrence. Because HCC is a heterogeneous disease with substantially variable clinical outcomes, the search for effective biomarkers to predict recurrence and prognosis is crucial.
Recent studies have demonstrated the importance of long non-coding RNAs (lncRNAs) in physiological and pathological cellular processes. Increasing evidence suggests that lncRNA dysregulation is associated with various human diseases, particularly the initiation and progression of various human cancers. For patients with HCC, most of the existing prognostic signatures have focused on mRNAs or microRNAs, and only a few lncRNA signatures have been developed. In the present study, we aimed to construct a lncRNA signature for the prediction of HCC prognosis with high efficiency.
To construct a lncRNA signature for the prediction of HCC prognosis with high efficiency.
Differentially expressed lncRNAs (DELs) between HCC specimens and peritumor liver specimens were acquired from the The Cancer Genome Atlas (TCGA) LIHC dataset using the edgeR package. Univariate Cox proportional hazards regression was performed to identify the DELs that were significantly associated with overall survival for the training set. The stepwise multivariate Cox regression model was applied. Those lncRNAs fitted in the multivariate Cox regression model and independently associated with overall survival were chosen to build a prognostic risk formula. The prognostic value of this formula was validated in the test group and the full cohort and further compared with two previously developed prognostic signatures for HCC.
We identified a five-lncRNA prognostic signature from the TCGA dataset and determined that its prognostic value was independent from clinicopathological factors. The signature was reproducible and robust in another independent large-scale HCC cohort, supporting its utility and effectiveness.
This study constructed a 5-lncRNA signature that improves survival prediction, and can be used as a prognostic biomarker for HCC patients.